Human KRT8(Keratin 8) ELISA Kit

Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Keratin 8 (KRT8) in serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids.

Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Keratin 8 (KRT8) in serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids.

Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Keratin 8 (KRT8) in serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids.

Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Keratin 8 (KRT8) in serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids.

Description: Enzyme-linked immunosorbent assay based on the Double-antibody Sandwich method for detection of Human Keratin 8 (KRT8) in samples from Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids with no significant corss-reactivity with analogues from other species.

Description: A sandwich ELISA kit for detection of Keratin 8 from Human in samples from blood, serum, plasma, cell culture fluid and other biological fluids.

Description: Recombinant Human Keratin 8 expressed in: E.coli

Description: Recombinant Rat Keratin 8 expressed in: E.coli

Description: Recombinant Rat Keratin 8 expressed in: E.coli

Description: A Mouse monoclonal antibody against Human Keratin 8 (KRT8)

Description: A Rabbit polyclonal antibody against Human, Rat Keratin 8 (KRT8)

Description: A Rabbit polyclonal antibody against Human, Rat Keratin 8 (KRT8)

Description: A Rabbit polyclonal antibody against Human, Rat Keratin 8 (KRT8)

Description: A Mouse monoclonal antibody against Human Keratin 8 (KRT8). This antibody is labeled with APC.

Description: A Mouse monoclonal antibody against Human Keratin 8 (KRT8). This antibody is labeled with Biotin.

Description: A Mouse monoclonal antibody against Human Keratin 8 (KRT8). This antibody is labeled with Cy3.

Description: A Mouse monoclonal antibody against Human Keratin 8 (KRT8). This antibody is labeled with FITC.

Description: A Mouse monoclonal antibody against Human Keratin 8 (KRT8). This antibody is labeled with HRP.

Description: A Mouse monoclonal antibody against Human Keratin 8 (KRT8). This antibody is labeled with PE.

Description: Quantitative sandwich ELISA for measuring Human Keratin, type II cytoskeletal 8 (KRT8) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.

Description: Quantitative sandwich ELISA for measuring Human Keratin, type II cytoskeletal 8 (KRT8) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.

Description: Quantitative sandwich ELISA for measuring Human Keratin, type II cytoskeletal 8 (KRT8) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.

Description: A Rabbit polyclonal antibody against Human, Rat Keratin 8 (KRT8). This antibody is labeled with APC.

Description: A Rabbit polyclonal antibody against Human, Rat Keratin 8 (KRT8). This antibody is labeled with Biotin.

Description: A Rabbit polyclonal antibody against Human, Rat Keratin 8 (KRT8). This antibody is labeled with Cy3.

Description: A Rabbit polyclonal antibody against Human, Rat Keratin 8 (KRT8). This antibody is labeled with FITC.

Description: A Rabbit polyclonal antibody against Human, Rat Keratin 8 (KRT8). This antibody is labeled with HRP.

Description: A Rabbit polyclonal antibody against Human, Rat Keratin 8 (KRT8). This antibody is labeled with PE.

Description: A Rabbit polyclonal antibody against Human, Rat Keratin 8 (KRT8). This antibody is labeled with APC.

Description: A Rabbit polyclonal antibody against Human, Rat Keratin 8 (KRT8). This antibody is labeled with Biotin.

Description: A Rabbit polyclonal antibody against Human, Rat Keratin 8 (KRT8). This antibody is labeled with Cy3.

Description: A Rabbit polyclonal antibody against Human, Rat Keratin 8 (KRT8). This antibody is labeled with FITC.

Description: A Rabbit polyclonal antibody against Human, Rat Keratin 8 (KRT8). This antibody is labeled with HRP.

Description: A Rabbit polyclonal antibody against Human, Rat Keratin 8 (KRT8). This antibody is labeled with PE.

Description: A Rabbit polyclonal antibody against Human, Rat Keratin 8 (KRT8). This antibody is labeled with APC.

Description: A Rabbit polyclonal antibody against Human, Rat Keratin 8 (KRT8). This antibody is labeled with Biotin.

Description: A Rabbit polyclonal antibody against Human, Rat Keratin 8 (KRT8). This antibody is labeled with Cy3.

Description: A Rabbit polyclonal antibody against Human, Rat Keratin 8 (KRT8). This antibody is labeled with FITC.

Description: A Rabbit polyclonal antibody against Human, Rat Keratin 8 (KRT8). This antibody is labeled with HRP.

Description: A Rabbit polyclonal antibody against Human, Rat Keratin 8 (KRT8). This antibody is labeled with PE.

Description: A Mouse monoclonal antibody against Human Keratin 8 (KRT8). This antibody is labeled with APC-Cy7.

Description: A Rabbit polyclonal antibody against Human, Rat Keratin 8 (KRT8). This antibody is labeled with APC-Cy7.

Description: A Rabbit polyclonal antibody against Human, Rat Keratin 8 (KRT8). This antibody is labeled with APC-Cy7.

Description: A Rabbit polyclonal antibody against Human, Rat Keratin 8 (KRT8). This antibody is labeled with APC-Cy7.

Description: Recombinant Human Keratin,type II cytoskeletal 8(KRT8),partial expressed in E.coli

Description: A competitive ELISA for quantitative measurement of Human THSD7a in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), CF405S conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), CF405S conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), PerCP conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), RPE conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), CF594 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), CF594 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), APC conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), CF680R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), CF680R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), Biotin conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), Biotin conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), CF488A conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), CF488A conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), CF660R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), CF660R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), CF568 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), CF568 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), CF543 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), CF543 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), CF640R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), CF640R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), CF555 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), CF555 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), CF680 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), CF680 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), CF405M conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), CF405M conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), CF770 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), CF770 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), CF647 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), CF647 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), Concentration: 0.2mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), 1mg/mL

Description: Primary antibody against Cytokeratin 8 (KRT8) (KRT8/2174R), Concentration: 0.2mg/mL

Description: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). CK8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibodies that recognize only cytokeratin 8 and 18. CK8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium. Anti-CK8 does not react with skeletal muscle or nerve cells. Epithelioid sarcoma, chordoma, and adamantinoma show strong positivity corresponding to that of simple epithelia (with antibodies against CK8, CK18 and CK19). Anti-CK8 is useful for the differentiation of lobular ( ring-like, perinuclear ) from ductal ( peripheral-predominant ) carcinoma of the breast.

Description: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). CK8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibodies that recognize only cytokeratin 8 and 18. CK8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium. Anti-CK8 does not react with skeletal muscle or nerve cells. Epithelioid sarcoma, chordoma, and adamantinoma show strong positivity corresponding to that of simple epithelia (with antibodies against CK8, CK18 and CK19). Anti-CK8 is useful for the differentiation of lobular ( ring-like, perinuclear ) from ductal ( peripheral-predominant ) carcinoma of the breast.

Description: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). CK8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibodies that recognize only cytokeratin 8 and 18. CK8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium. Anti-CK8 does not react with skeletal muscle or nerve cells. Epithelioid sarcoma, chordoma, and adamantinoma show strong positivity corresponding to that of simple epithelia (with antibodies against CK8, CK18 and CK19). Anti-CK8 is useful for the differentiation of lobular ( ring-like, perinuclear ) from ductal ( peripheral-predominant ) carcinoma of the breast.

Description: Cytokeratin 8 (also called CK8, Keratin 8 and KRT8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). CK8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibodies that recognize only cytokeratin 8 and 18. CK8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium. Anti-CK8 does not react with skeletal muscle or nerve cells. Epithelioid sarcoma, chordoma, and adamantinoma show strong positivity corresponding to that of simple epithelia (with antibodies against CK8, CK18 and CK19). Anti-CK8 is useful for the differentiation of lobular (ring-like, perinuclear) from ductal (peripheral-predominant) carcinoma of the breast.

Description: Cytokeratin 8 (also called CK8, Keratin 8 and KRT8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). CK8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibodies that recognize only cytokeratin 8 and 18. CK8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium. Anti-CK8 does not react with skeletal muscle or nerve cells. Epithelioid sarcoma, chordoma, and adamantinoma show strong positivity corresponding to that of simple epithelia (with antibodies against CK8, CK18 and CK19). Anti-CK8 is useful for the differentiation of lobular (ring-like, perinuclear) from ductal (peripheral-predominant) carcinoma of the breast.

Description: Cytokeratin 8 (also called CK8, Keratin 8 and KRT8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). CK8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibodies that recognize only cytokeratin 8 and 18. CK8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium. Anti-CK8 does not react with skeletal muscle or nerve cells. Epithelioid sarcoma, chordoma, and adamantinoma show strong positivity corresponding to that of simple epithelia (with antibodies against CK8, CK18 and CK19). Anti-CK8 is useful for the differentiation of lobular (ring-like, perinuclear) from ductal (peripheral-predominant) carcinoma of the breast.

Description: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). CK8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibodies that recognize only cytokeratin 8 and 18. CK8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium. Anti-CK8 does not react with skeletal muscle or nerve cells. Epithelioid sarcoma, chordoma, and adamantinoma show strong positivity corresponding to that of simple epithelia (with antibodies against CK8, CK18 and CK19). Reportedly, anti-CK8 is useful for the differentiation of lobular ('ring-like, perinuclear') from ductal ('peripheral-predominant') carcinoma of the breast.

Description: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). CK8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibodies that recognize only cytokeratin 8 and 18. CK8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium. Anti-CK8 does not react with skeletal muscle or nerve cells. Epithelioid sarcoma, chordoma, and adamantinoma show strong positivity corresponding to that of simple epithelia (with antibodies against CK8, CK18 and CK19). Reportedly, anti-CK8 is useful for the differentiation of lobular ('ring-like, perinuclear') from ductal ('peripheral-predominant') carcinoma of the breast.

Description: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). CK8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibodies that recognize only cytokeratin 8 and 18. CK8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium. Anti-CK8 does not react with skeletal muscle or nerve cells. Epithelioid sarcoma, chordoma, and adamantinoma show strong positivity corresponding to that of simple epithelia (with antibodies against CK8, CK18 and CK19). Reportedly, anti-CK8 is useful for the differentiation of lobular ('ring-like, perinuclear') from ductal ('peripheral-predominant') carcinoma of the breast.

Description: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). CK8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibodies that recognize only cytokeratin 8 and 18. CK8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium. Anti-CK8 does not react with skeletal muscle or nerve cells. Epithelioid sarcoma, chordoma, and adamantinoma show strong positivity corresponding to that of simple epithelia (with antibodies against CK8, CK18 and CK19). Reportedly, anti-CK8 is useful for the differentiation of lobular ('ring-like, perinuclear') from ductal ('peripheral-predominant') carcinoma of the breast.

Description: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). CK8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibodies that recognize only cytokeratin 8 and 18. CK8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium. Anti-CK8 does not react with skeletal muscle or nerve cells. Epithelioid sarcoma, chordoma, and adamantinoma show strong positivity corresponding to that of simple epithelia (with antibodies against CK8, CK18 and CK19). Reportedly, anti-CK8 is useful for the differentiation of lobular ('ring-like, perinuclear') from ductal ('peripheral-predominant') carcinoma of the breast.

Description: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). CK8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibodies that recognize only cytokeratin 8 and 18. CK8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium. Anti-CK8 does not react with skeletal muscle or nerve cells. Epithelioid sarcoma, chordoma, and adamantinoma show strong positivity corresponding to that of simple epithelia (with antibodies against CK8, CK18 and CK19). Reportedly, anti-CK8 is useful for the differentiation of lobular ('ring-like, perinuclear') from ductal ('peripheral-predominant') carcinoma of the breast.

Description: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). CK8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibodies that recognize only cytokeratin 8 and 18. CK8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium. Anti-CK8 does not react with skeletal muscle or nerve cells. Epithelioid sarcoma, chordoma, and adamantinoma show strong positivity corresponding to that of simple epithelia (with antibodies against CK8, CK18 and CK19). Reportedly, anti-CK8 is useful for the differentiation of lobular ('ring-like, perinuclear') from ductal ('peripheral-predominant') carcinoma of the breast.

Description: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). CK8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibodies that recognize only cytokeratin 8 and 18. CK8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium. Anti-CK8 does not react with skeletal muscle or nerve cells. Epithelioid sarcoma, chordoma, and adamantinoma show strong positivity corresponding to that of simple epithelia (with antibodies against CK8, CK18 and CK19). Reportedly, anti-CK8 is useful for the differentiation of lobular ('ring-like, perinuclear') from ductal ('peripheral-predominant') carcinoma of the breast.

Description: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). CK8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibodies that recognize only cytokeratin 8 and 18. CK8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium. Anti-CK8 does not react with skeletal muscle or nerve cells. Epithelioid sarcoma, chordoma, and adamantinoma show strong positivity corresponding to that of simple epithelia (with antibodies against CK8, CK18 and CK19). Reportedly, anti-CK8 is useful for the differentiation of lobular (ring-like, perinuclear) from ductal (peripheral-predominant) carcinoma of the breast.

Description: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). CK8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibodies that recognize only cytokeratin 8 and 18. CK8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium. Anti-CK8 does not react with skeletal muscle or nerve cells. Epithelioid sarcoma, chordoma, and adamantinoma show strong positivity corresponding to that of simple epithelia (with antibodies against CK8, CK18 and CK19). Reportedly, anti-CK8 is useful for the differentiation of lobular (ring-like, perinuclear) from ductal (peripheral-predominant) carcinoma of the breast.

Description: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). CK8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibodies that recognize only cytokeratin 8 and 18. CK8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium. Anti-CK8 does not react with skeletal muscle or nerve cells. Epithelioid sarcoma, chordoma, and adamantinoma show strong positivity corresponding to that of simple epithelia (with antibodies against CK8, CK18 and CK19). Reportedly, anti-CK8 is useful for the differentiation of lobular (ring-like, perinuclear) from ductal (peripheral-predominant) carcinoma of the breast.

Description: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). CK8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibodies that recognize only cytokeratin 8 and 18. CK8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium. Anti-CK8 does not react with skeletal muscle or nerve cells. Epithelioid sarcoma, chordoma, and adamantinoma show strong positivity corresponding to that of simple epithelia (with antibodies against CK8, CK18 and CK19). Reportedly, anti-CK8 is useful for the differentiation of lobular (ring-like, perinuclear) from ductal (peripheral-predominant) carcinoma of the breast.

Description: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). CK8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibodies that recognize only cytokeratin 8 and 18. CK8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium. Anti-CK8 does not react with skeletal muscle or nerve cells. Epithelioid sarcoma, chordoma, and adamantinoma show strong positivity corresponding to that of simple epithelia (with antibodies against CK8, CK18 and CK19). Reportedly, anti-CK8 is useful for the differentiation of lobular (ring-like, perinuclear) from ductal (peripheral-predominant) carcinoma of the breast.

Description: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). CK8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibodies that recognize only cytokeratin 8 and 18. CK8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium. Anti-CK8 does not react with skeletal muscle or nerve cells. Epithelioid sarcoma, chordoma, and adamantinoma show strong positivity corresponding to that of simple epithelia (with antibodies against CK8, CK18 and CK19). Reportedly, anti-CK8 is useful for the differentiation of lobular (ring-like, perinuclear) from ductal (peripheral-predominant) carcinoma of the breast.

Description: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). CK8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibodies that recognize only cytokeratin 8 and 18. CK8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium. Anti-CK8 does not react with skeletal muscle or nerve cells. Epithelioid sarcoma, chordoma, and adamantinoma show strong positivity corresponding to that of simple epithelia (with antibodies against CK8, CK18 and CK19). Reportedly, anti-CK8 is useful for the differentiation of lobular (ring-like, perinuclear) from ductal (peripheral-predominant) carcinoma of the breast.

Description: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). CK8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibodies that recognize only cytokeratin 8 and 18. CK8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium. Anti-CK8 does not react with skeletal muscle or nerve cells. Epithelioid sarcoma, chordoma, and adamantinoma show strong positivity corresponding to that of simple epithelia (with antibodies against CK8, CK18 and CK19). Reportedly, anti-CK8 is useful for the differentiation of lobular (ring-like, perinuclear) from ductal (peripheral-predominant) carcinoma of the breast.

Description: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). CK8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibodies that recognize only cytokeratin 8 and 18. CK8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium. Anti-CK8 does not react with skeletal muscle or nerve cells. Epithelioid sarcoma, chordoma, and adamantinoma show strong positivity corresponding to that of simple epithelia (with antibodies against CK8, CK18 and CK19). Anti-CK8 is useful for the differentiation of lobular (ring-like, perinuclear) from ductal (peripheral-predominant) carcinoma of the breast.

Description: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). CK8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibodies that recognize only cytokeratin 8 and 18. CK8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium. Anti-CK8 does not react with skeletal muscle or nerve cells. Epithelioid sarcoma, chordoma, and adamantinoma show strong positivity corresponding to that of simple epithelia (with antibodies against CK8, CK18 and CK19). Anti-CK8 is useful for the differentiation of lobular (ring-like, perinuclear) from ductal (peripheral-predominant) carcinoma of the breast.

Description: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). CK8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibodies that recognize only cytokeratin 8 and 18. CK8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium. Anti-CK8 does not react with skeletal muscle or nerve cells. Epithelioid sarcoma, chordoma, and adamantinoma show strong positivity corresponding to that of simple epithelia (with antibodies against CK8, CK18 and CK19). Anti-CK8 is useful for the differentiation of lobular (ring-like, perinuclear) from ductal (peripheral-predominant) carcinoma of the breast.

Description: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). CK8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibodies that recognize only cytokeratin 8 and 18. CK8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium. Anti-CK8 does not react with skeletal muscle or nerve cells. Epithelioid sarcoma, chordoma, and adamantinoma show strong positivity corresponding to that of simple epithelia (with antibodies against CK8, CK18 and CK19). Anti-CK8 is useful for the differentiation of lobular (ring-like, perinuclear) from ductal (peripheral-predominant) carcinoma of the breast.

Description: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). Cytokeratin 8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibody that recognizes only cytokeratin 8 and 18. Cytokeratin 8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium.

Description: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). Cytokeratin 8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibody that recognizes only cytokeratin 8 and 18. Cytokeratin 8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium.

Description: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). Cytokeratin 8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibody that recognizes only cytokeratin 8 and 18. Cytokeratin 8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium.

Description: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). Cytokeratin 8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibody that recognizes only cytokeratin 8 and 18. Cytokeratin 8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium.

Description: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). Cytokeratin 8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibody that recognizes only cytokeratin 8 and 18. Cytokeratin 8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium.

Description: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). Cytokeratin 8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibody that recognizes only cytokeratin 8 and 18. Cytokeratin 8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium.

Description: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). Cytokeratin 8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibody that recognizes only cytokeratin 8 and 18. Cytokeratin 8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium.

Description: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). Cytokeratin 8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibody that recognizes only cytokeratin 8 and 18. Cytokeratin 8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium.

Description: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). Cytokeratin 8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibody that recognizes only cytokeratin 8 and 18. Cytokeratin 8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium.

Description: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). Cytokeratin 8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibody that recognizes only cytokeratin 8 and 18. Cytokeratin 8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium.

Description: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). Cytokeratin 8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibody that recognizes only cytokeratin 8 and 18. Cytokeratin 8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium.

Description: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). Cytokeratin 8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibody that recognizes only cytokeratin 8 and 18. Cytokeratin 8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium.

Description: Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). Cytokeratin 8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibody that recognizes only cytokeratin 8 and 18. Cytokeratin 8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium. antibody to Cytokeratin 8 does not react with skeletal muscle or nerve cells. Epithelioid sarcoma, chordoma, and adamantinoma show strong positivity corresponding to that of simple epithelia (with antibodies against Cytokeratin 8, 18 and 19). Reportedly, Cytokeratin 8 antibody is useful for the differentiation of lobular (“ring-like, perinuclear”) from ductal (“peripheral-predominant”) carcinoma of the breast.